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Background: Rheumatoid arthritis (RA) is a systemic autoimmunedisorderwith a variety of extra-
articular manifestations. The lung is a common target and diffuse parenchymal lung disease can
appear as any of the patterns found with idiopathic interstitial pneumonia. Controversy exists as
to the prognostic significance of these patterns among patients with RA-ILD.
Methods: We retrospectively identified 48 patients with a diagnosis of RA-ILD confirmed by sur-
gical lung biopsy. The pathology was reviewed by four expert pulmonary pathologists. We exam-
ined survival after stratifying on the presence or absence of fibrotic ILD, and contrasted it with a
matched idiopathic pulmonary fibrosis (IPF) population. The Cox proportional hazardsmodelwas
used to identify independent predictors of survival.
Results: The majority of subjects were male smokers with physiologic restriction. A usual inter-
stitial pneumonia (UIP)-pattern was identified in 31% of subjects. Median survival time for theLung Center and ILD Program, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA.
alth.org (J.J. Solomon), ryu.jay@mayo.edu (J.H. Ryu), tazelaar.henry@mayo.edu (H.D. Tazelaar),
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1248 J.J. Solomon et al.entire cohort was 1360 days. Subjects with fibrotic ILD hadworse survival than subjects with non-
fibrotic ILD (log rank pZ 0.02). There was no difference in survival between UIP-pattern RA-ILD
subjects and IPF controls (log rank pZ 0.94). Multivariable analysis revealed that age (hazard
ratio [HR]Z 1.04, pZ 0.01) and fibrosis (HRZ 2.1, pZ 0.02) were independent predictors of
mortality.
Conclusions: Both cellular and fibrosing ILD patterns are common among RA-ILD patients who un-
dergo surgical lung biopsy. These patients have a shortened survival when compared to the gen-
eral population and all-comers with RA. Age and the presence of a fibrosing interstitial
pneumonia predict shortened survival in these patients. Survival in UIP is similar to matched
IPF patients.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Rheumatoid arthritis (RA) is a common systemic autoim-
mune disorder characterized by severe inflammatory
arthritis. Over two million adultsdapproximately 1% of the
adult populationdin the United States have RA. Its inci-
dence ranges from 12 to 70/100,000 patient-years in men
and 25e130/100,000 in women. A major portion of RA dis-
ease burden, particularly the excess mortality, appears to
be due to extra-articular manifestations (exRA).1,2 The
extra-articular manifestations are common (the prevalence
of clinically “severe” exRA approaches 40% in some
studies3) and accumulate over a patient’s lifetime at an
incidence of 1e3 distinct exRA/100 patient-years.4
Although cardiovascular disease is responsible for the
majority of RA-related deaths,5 pulmonary complications
are common, directly responsible for 10e20% of deaths6e8
and increasing in frequency.9 While pulmonary infection
anddrug-induced lungdisease occur,10,11 RA can also directly
affect the lung with any pulmonary compartmentdairways,
pulmonary vasculature, pleura, or parenchyma e at risk.
Interstitial lung disease (ILD) in RAwas first described in 1948
by Ellman and Ball12 and more systematically evaluated in
several subsequent studies.13e18 The prevalence of RA-ILD
varies based on the population studied, how the condition
is defined, and the sensitivity of the detection methods.
Yousem and colleagues19 were the first to report that
among RA patients with diffuse parenchymal lung disease,
those with a histologic pattern of usual interstitial pneumonia
(UIP) in surgical lung biopsy specimens had the worst prog-
nosis. Results from subsequent studies have confirmed their
findings20,21; however, data on whether patients with RA-
related UIP-pattern lung injury have prognoses similar to or
better than patients with idiopathic pulmonary fibrosis (IPF)
are conflicting.14,22e28 We sought to determine the effect of
histologicpattern in surgical lung biopsy specimens on survival
of patients with RA-ILD. We hypothesized that the histo-
pathologic pattern would define prognosis and that subjects
with fibrosing lung disease would have the worst prognosis.Methods
Study population
The databases of the ILD programs at National Jewish
Health (NJH) (N Z 22) and the Mayo Clinic (N Z 34) wereretrospectively queried for subjects with a confirmed
diagnosis of RA who had undergone surgical lung biopsy for
the further evaluation of diffuse parenchymal lung disease
between 1977 and 1999 (56 subjects in total). Approval for
this study was obtained through the National Jewish Insti-
tutional Review Board (approval number HS-1603) and the
Mayo Clinic Institutional Review Board (approval number
1184-00). All subjects were evaluated by a board certified
rheumatologist and met the revised criteria for RA set forth
by the American College of Rheumatology.29 Patients
without ILD (n Z 1) or alternate diagnoses, such as pul-
monary edema (n Z 1), infectious pneumonia (n Z 3),
Wegener’s granulomatosis (nZ 1), blastomycosis (nZ 1) or
emphysema (n Z 1) were excluded. The final cohort con-
sisted of 48 subjects. A matched control population of 11
subjects with a surgical lung biopsy confirmed diagnosis of
IPF was obtained from the NJ Health ILD database. Each
subject signed an informed consent to have their data and
specimens stored in a research database for later use, and
the Institutional Review Boards of NJH and the Mayo Clinic
approved the protocol.
Pulmonary function assessment
Pulmonary function testing was performed according to
American Thoracic Society (ATS) standards and included
forced expiratory volume in the first second (FEV1), forced
vital capacity (FVC), diffusion capacity for carbon monox-
ide (DLCO) and total lung capacity (TLC). Values were
expressed as a percentage of normal (e.g., FEV1%, FVC%,
DLCO%, and TLC%) predicted from the patient’s height, age
and gender. Only physiology obtained within two months of
the date of diagnosis was included in the analysis.
Pathologic assessment
Surgical lung biopsy specimens were processed in routine
fashion, and the original slides were reviewed by four
expert pulmonary pathologists (CC, RT, HT, JM) blinded to
clinical, radiologic or physiologic findings. A consensus
pattern diagnosis was made from the following list of injury
patterns based on ATS/ERS criteria30: bronchiolitis, diffuse
alveolar damage (DAD), desquamative interstitial pneu-
monia (DIP), lymphoid interstitial pneumonia (LIP), cellular
nonspecific interstitial pneumonia (cNSIP), fibrotic
nonspecific interstitial pneumonia (fNSIP), organizing
pneumonia (OP), unclassifiable fibrosing interstitial lung
Table 1 Baseline demographics. Baseline demographics
for patients grouped by the presence or absence of fibrosis
on biopsy.
Fibrotic
ILD
Non-fibrotic
ILD
Total
RA-ILD mortality 1249disease (uILD) and usual interstitial pneumonia (UIP). For
purpose of analysis, patients with fNSIP, uILD or UIP-pattern
histology were grouped together under the title “fibrotic”
(NZ 23), and those with bronchiolitis, DAD, DIP, LIP, cNSIP
and OP patterns were grouped under the title “non-
fibrotic” (N Z 25).N 23 25 48
Age, yra 61 (11.1) 59 (11.1) 60 (11.1)
Gender
Male 15 12 27
Female 8 13 21
Smoking Status
Never 6 12 18
Former 11 6 17
Current 4 3 7
Unknown 2 4 6
Pathology (N ) fNSIP (4)
uILD (4)
UIP (15)
Bronchiolitis (6)
DAD (6)
DIP (3)
LIP (1)
cNSIP (2)
OP (7)
Physiology
%FEV1
a 65 (23.1) 57 (25.8) 61 (24.2)
%FVCa 64 (17.5) 59 (18.5) 61 (17.9)
FEV1/FVC
a 76% (16.2) 76% (18) 76 (16.8)
%DLCOa 41 (12.6) 55 (13.4) 48 (12.6)
%TLCa 68 (10.5) 77 (20.5) 73 (17)
a Continuous variables are expressed as mean (standard
deviation).Statistical methods
Counts or measures of central tendency were determined
for baseline characteristics. We used the product-limit
method to derive and KaplaneMeier curves to display sur-
vival for the sample as a whole; after stratifying on the
presence or absence of fibrotic ILD; and for FVC- and DLCO-
matched IPF controls. We used the log-rank test to test for
statistically significant differences between survival curves.
We performed a side-by-side comparison of the survival
curve from our cohort with two from a study by Turesson
and colleagues (“RA Cohort” e 412 patients with RA; and
“exRA”d169 patients who developed extra-articular man-
ifestations31) and “Age Cohort”dage-matched and derived
from United States white population life tables. We used
Cox proportional-hazards regression to assess the impact of
lung fibrosis (i.e., “fibrotic” vs. “non-fibrotic”) on survival
while controlling for other potentially important pre-
dictors. The assumption of proportional hazards for the
main effect (i.e., “fibrotic” vs. “non-fibrotic”) was
confirmed with a log(log) plot. Bivariate analyses were
run on candidate variables; those with p < 0.15 were
included in the final multivariable model. To develop the
most parsimonious model, we used candidate variable se-
lection techniques. We ensured model stability by using
stepwise, forward and backward (entry of any variable with
a p-value<0.15 and retained any variable with a p-value
<0.15) techniques in the “selectionZ” option in SAS PROC
PHREG. We considered p < 0.05 to represent statistical
significance. All data analyses were performed using SAS
Version 9.1 (SAS Institute, Cary, NC).0.75
0.50
0.25
1.00
Probability of Survival
Age cohort
Turesson et al. RA cohortResults
Baseline demographics, histopathologic findings
and physiology
Baseline demographics of the cohort stratified on the
presence or absence of fibrosis are listed in Table 1. Over
half the subjects were male. Most were current or former
smokers. A UIP-pattern was identified in 31% of subjects.
DIP (6%) and LIP (2%) were rarely identified. The majority of
subjects had restrictive physiology and impaired diffusion
on pulmonary function studies.Days of Follow-up after Lung Biopsy
0 2000 4000 6000 8000
0.00 RA-ILD
exRA
Figure 1 Kaplan Meier curves comparing patients with RA
and ILD (RA-ILD), RA with all extra-articular manifestations
(exRA), all-comers with RA (RA cohort) and age matched con-
trols (age cohort).Survival
The overall survival of all patients in the cohort is shown in
Fig. 1. Median survival was 1360 days, and there were 40
deaths during this time. Survival for the entire cohort
appeared similar to that for historical control subjects with
exRA, worse than all-comers with RA31 and worse than age-matched controls from the general population (the Age
Cohort).31
Effect of fibrosis on survival
Subjects with fibrotic RA-ILD had worse survival than sub-
jects with non-fibrotic ILD (Fig. 2, log-rank p Z 0.02).
Days of Follow-up after Lung Biopsy
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Probability of Survival
Other RA
Fibrotic
Figure 2 Kaplan Meier curves comparing RA patients with
and without fibrotic ILD (log rank p Z 0.02).
Table 2 Potential predictors of survival and results of
bivariate analyses.
Hazard
ratio
Confidence
interval
p-value
TLC 1.0 0.98e1.02 0.9
FVC 0.9 0.98e1.01 0.5
DLCO 0.9 0.98e1.01 0.5
Age 1.04 1.01e1.07 0.01
Gender 1.8 0.92e3.41 0.08
Presence of
fibrosis
2.1 1.11e4.26 0.02
1250 J.J. Solomon et al.Survival for subjects with RA-UIP (Fig. 3) was similar to that
of FVC- and DLCO-matched historical controls with IPF (log-
rank p Z 0.94). Results of the bivariate analyses are dis-
played in Table 2. In a multivariable model that included
potentially influential predictors (as determined by the
bivariate analyses) and was the same regardless of the se-
lection technique used, the only two independent pre-
dictors of mortality were age and the presence of fibrosis.
Thus, even when controlling for age (hazard ratio
[HR] Z 1.04, p Z 0.01) the presence of lung fibrosis
(HR Z 2.1, p Z 0.02) was an independent predictor of
mortality. There was no difference in survival for patients
with UIP, fNSIP or uILD (data not shown).Days of Follow-up after Lung Biopsy
0 1000 2000 3000 4000
0.75
0.50
0.25
0.00
1.00
Probability of Survival
RA-ILD
IPF
UIP
Figure 3 Kaplan Meier curves comparing RA-UIP with FVC-
and DLCO matched historical controls with IPF (log rank
p Z 0.94).Discussion
Histologically confirmed ILD in patients with RA confers a
prognosis much worse than that seen in an age-matched
healthy control population and worse than for all-comers
with RA. The majority of our study group had histologic
patterns of injury classifiable by current ATS/ERS consensus
guidelines for the idiopathic interstitial pneumonias (IIP).30
UIP was the most common pattern of interstitial pneu-
monia, accounting for nearly a third of all biopsies and two
thirds of those with established lung fibrosis.
The presence of fibrosis in surgical lung biopsies from
patients with RA is associated with shortened survival. In
our cohort, patients with fibrotic forms of RA-ILD had a risk
of dying two times the risk of RA patients with non-fibrotic
lung disease. Baseline pulmonary physiology was not a
predictor of survival, but histologic pattern (or more pre-
cisely, the presence of fibrosis, regardless of specific injury
pattern) was. We included fNSIP in a category of patients
that included UIP and uILD for a number of reasons. In
patients with idiopathic interstitial pneumonia (IIP), those
with fNSIP on surgical lung biopsy have a worse prognosis
compared to cNSIP.32 Also, survival is better for patients
with fNSIP compared to those with UIP at 5 years, but this
difference decreases at the 10-year mark (10-year survival
for fNSIP is 35% compared to 15% for UIP).33 In our patients,
there was no difference in survival in patients with fNSIP
when compared to uILD or UIP (data not shown).
We observed no statistically significant difference in
survival between subjects with RA-UIP and matched IPF
controls. Our results add to the ongoing debate on whether
UIP in patients with connective tissue disease (CTD) carries
a prognosis different from IPF. Turesson et al. reviewed 424
cases of RA and concluded that most of the excess mortality
occurred in patients with extra-articular manifestations
(including pleuritis, pulmonary fibrosis and organizing
pneumonia).31 Subjects in our cohort had survival that
paralleled survival in subjects with all exRA.
Other investigators have compared the survival of pa-
tients with connective tissue disease-related ILD (CTD-ILD)
to survival for patients with idiopathic interstitial pneu-
monia. Hubbard and colleagues performed a survival anal-
ysis of patients from the U.K. General Practice Research
Database and found that survival among patients with CTD-
related fibrosing ILD (80% with RA) was similar to that for
IPFdeach group had an average survival of less than three
years.26 Lee and co-investigators examined 18 patients with
RA-ILD mortality 1251RA who underwent surgical lung biopsy and observed that a
UIP-pattern was most common.21 Over a median of 50
months of follow-up, the only deaths they observed (NZ 5)
were in the subgroup with UIP-pattern histology. Rajase-
karan and colleagues observed better survival among 18
patients with RA-related ILD (either “alveolitis” or fibrosis
on HRCT scan) than among controls with IPF (60 mos vs
27 mos, pZ <0.05).27 Park and colleagues have conducted
the largest study aimed at comparing the clinical features
and survival of subjects with CTD-ILD to those among sub-
jects with IIP. They observed longer survival for subjects
with CTD-ILD than IIP and, contrary to previous assertions,
the effect was not solely because of a higher incidence of
NSIP-pattern pathology among those with CTD; rather, it
was largely due to significantly better survival in subjects
with CTD-UIP than those with IPF.28 Interestingly, they
observed no difference in survival between the subgroup of
subjects with RA-UIP and those with IPF. Recently, Song and
colleagues identified the presence of RA as the only sig-
nificant predictor of survival among a cohort consisting of
subjects with various CTD and UIP-pattern histology.34
There are limitations to this study. Selecting subjects
from the two academic referral centers could introduce
tertiary referral bias. There also is an inherent selection
bias in our subjects with RA-ILD; they represent a subset of
RA patients with either severe pulmonary symptoms or
atypical features that led to a surgical lung biopsy. Whether
the results translate to patients without symptoms and
subtle chest imaging abnormalities, or those with symptoms
and ILD on chest imaging that have not undergone surgical
lung biopsy requires further investigation. The impact of
fibrosis on survival may be a more general phenomenon in
ILD and not specific to RA-ILD. Indeed, fibrosis has been
shown to impact survival in other ILDs.33,35,36 The small
number of subjects limits our ability to detect other dif-
ferences between the groups that may have impacted
survival. Another limitation relates to more precise char-
acterization of the RA phenotype of these subjects. Auto-
antibody test data were not available on these subjects and
this cohort predates the routine use of anti-cyclic citrulli-
nated peptide (anti-CCP) testing. Because it is not
yet known whether the presence of rheumatoid factor or
anti-CCP antibodies convey and clinical significance in
regards to RA-ILD, it would be of interest to know the
autoantibody profile of this and subsequent cohorts of RA-
ILD. Other variables that were not measured such as
6 min walk distance and pulmonary artery pressures may
also have had an impact on survival. Finally, recent data
suggests that HRCT findings (a definite UIP pattern with
traction bronchiectasis and honeycomb fibrosis) are asso-
ciated with a worse survival.37 We were unable to analyze
the relationship between HRCT findings and outcome in this
cohort. It is possible that this association may be strong
enough to obviate the need for biopsy. Further studies are
needed to look at the specific pathologic subtypes in rela-
tion to clinical course and decline in pulmonary function as
well as the association of radiographic findings in compar-
ison with pathologic subtype with outcome. Despite these
limitations, this study has merits: it clarifies the usefulness
of histologic data in prognostication for patients with RA-
ILD and adds to the growing debate on survival differ-
ences between idiopathic and CTD-related ILD.In conclusion, we examined the effect of an underlying
pattern of fibrosis on the survival of patients with RA-ILD
and found an overall decreased survival in these patients,
while those with a UIP histologic pattern had an outcome
similar to those with IPF.
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